KUMEKAWA Y[au] - Search Results

Year	Number of Results
1974	2
1976	1
2001	1
2004	1
2006	2
2007	2
2010	1
2012	1
2013	1
2015	3
2016	2
2017	2
2018	2
2019	3
2020	3
2021	2

1

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.

Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y. Moriwaki T, et al. Among authors: kumekawa y. Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11. Oncologist. 2018. PMID: 28894015 Free PMC article.

2

Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review.

Yoshii T, Hara H, Asayama M, Kumekawa Y, Miyazawa S, Takahashi N, Matsushima T, Shimizu S, Saito Y. Yoshii T, et al. Among authors: kumekawa y. Mol Clin Oncol. 2020 Jan;12(1):23-30. doi: 10.3892/mco.2019.1945. Epub 2019 Oct 31. Mol Clin Oncol. 2020. PMID: 31814973 Free PMC article.

3

Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.

Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Moriwaki T, et al. Among authors: kumekawa y. Int J Clin Oncol. 2020 Apr;25(4):614-621. doi: 10.1007/s10147-019-01600-0. Epub 2019 Dec 14. Int J Clin Oncol. 2020. PMID: 31838590

4

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).

Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T. Suzuki T, et al. Among authors: kumekawa y. Clin Colorectal Cancer. 2020 Mar;19(1):13-21.e3. doi: 10.1016/j.clcc.2019.10.004. Epub 2019 Oct 23. Clin Colorectal Cancer. 2020. PMID: 31732439 Clinical Trial.

5

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.

Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E. Tsuchihashi K, et al. Among authors: kumekawa y. Clin Colorectal Cancer. 2018 Dec;17(4):e687-e697. doi: 10.1016/j.clcc.2018.07.004. Epub 2018 Jul 29. Clin Colorectal Cancer. 2018. PMID: 30149986

6

[Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy].

Osumi H, Shinozaki E, Kumekawa Y, Ogura M, Ozaka M, Suenaga M, Matsusaka S, Chin K, Mizunuma N, Yokoyama M. Osumi H, et al. Among authors: kumekawa y. Gan To Kagaku Ryoho. 2013 Nov;40(11):1557-60. Gan To Kagaku Ryoho. 2013. PMID: 24231715 Japanese.

7

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.

Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N. Osumi H, et al. Among authors: kumekawa y. Mol Clin Oncol. 2015 Sep;3(5):1053-1057. doi: 10.3892/mco.2015.602. Epub 2015 Jul 9. Mol Clin Oncol. 2015. PMID: 26623049 Free PMC article.

8

Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.

Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N. Osumi H, et al. Among authors: kumekawa y. Gastric Cancer. 2016 Apr;19(2):625-630. doi: 10.1007/s10120-015-0517-9. Epub 2015 Aug 11. Gastric Cancer. 2016. PMID: 26260873 Clinical Trial.

9

A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.

Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y, Koizumi W. Nakayama N, et al. Among authors: kumekawa y. Gastric Cancer. 2017 Mar;20(2):350-357. doi: 10.1007/s10120-016-0614-4. Epub 2016 May 17. Gastric Cancer. 2017. PMID: 27189323 Clinical Trial.

10

Interleukin-1beta gene in esophageal, gastric and colorectal carcinomas.

Ito H, Kaneko K, Makino R, Konishi K, Kurahashi T, Yamamoto T, Katagiri A, Kumekawa Y, Kubota Y, Muramoto T, Mitamura K, Imawari M. Ito H, et al. Among authors: kumekawa y. Oncol Rep. 2007 Aug;18(2):473-81. Oncol Rep. 2007. PMID: 17611673

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results